CollabRx | GenomeWeb

CollabRx

Under the terms of the deal, CollabRx will operate as a wholly owned subsidiary of the combined firm, and its shareholders will own 10 percent of the new company. 

The firms have inked a non-binding letter of intent to negotiate a merger, and Medytox has provided CollabRx with a loan.

NEW YORK (GenomeWeb) – CollabRx and Cartagenia have teamed up to provide an end-to-end software solution for clinical laboratories that supports genetic testing and reporting, including next-generation sequencing-based tests, in oncology.

The TranSmart Foundation has launched version 1.2 of its open-source knowledge management platform for life science research.

NEW YORK (GenomeWeb) – CollabRx said this week that Singapore-based private oncology firm OncoSolutions Cancer Center has signed a multi-year agreement to use CollabRx's Genetic Variant Annotation (GVA) service to analyze tumor genetic data.

CollabRx has launched CancerRx, a new oncology application that runs on Apple's operating system. The app provides oncologists and pathologists with treatment options that are based on their patients' tumors and also offers a daily newsfeed from MedPage Today.

MedPage Today and CollabRx have released CancerRx, an application that runs on Apple's operating system, that’s designed to help oncologists and pathologists navigate the complex landscape of oncology therapeutic options.

NEW YORK (GenomeWeb) – Sales of Affymetrix's CytoScan offering for chromosomal microarray analysis helped lift the vendor's first quarter revenues by 7 percent, the company said last week.

CollabRx has appointed Paul Billings to its board of directors. Billings most recently served as chief medical officer for Life Technologies.

NEW YORK (GenomeWeb) — A new agreement between Affymetrix and CollabRx that will allow clinical research labs to interpret microarray data within the architecture of CollabRx's Gene Variant Annotation Service showcases two market trends, according Gavin Gordon, CollabRx's vice president of busin

Pages

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.